Detailed Narrative
Q4 FY26 Performance Highlights
Epigral achieved its highest-ever revenue of INR 736 crores in Q4 FY26, marking a 22% quarter-on-quarter increase. This growth was primarily driven by a robust 15% QoQ and 14% YoY volume increase, supported by demand pickup from mid-November and optimal utilization of the caustic soda plant post-maintenance. The company's EBITDA for the quarter surged by 64% QoQ to INR 169 crores, with the EBITDA margin normalizing to 23% due to improved plant efficiency and stable raw material prices.
Full Year FY26 Review and Challenges
For the full fiscal year 2026, Epigral reported a marginal 1% decline in revenue to INR 2,542 crores, accompanied by a 4% drop in volume. This was attributed to a major maintenance shutdown in H1 FY26, prolonged monsoon conditions, and volatility in PVC prices impacting CPVC demand. Despite these challenges, the company achieved an EBITDA of INR 567 crores (22% margin) and an adjusted PAT of INR 252 crores (excluding a one-time📎 deferred tax benefit of INR 81 crores).
Capacity Expansion and Future Growth Drivers
Epigral's capacity expansion projects for Epichlorohydrin (ECH) and CPVC are progressing on schedule and within budget, with commissioning expected in Q2 FY27. Management anticipates these projects, along with Chlorotoluene (commissioned March 2025), to drive significant top and bottom-line growth, targeting a 10-12% volume growth for FY27. The company projects ECH and CPVC to reach optimum utilization levels of 80% and 75% respectively by FY28.
Strategic Focus on Specialty Chemicals and Captive Consumption
The contribution from derivatives and specialty businesses increased to 54% of revenue in Q4 FY26, up from 52% in the previous quarter, reflecting a strategic shift towards higher-margin products. Furthermore, the company aims to increase its chlorine captive consumption from the current 75% to 90-95% by FY28, leveraging the expanded ECH and CPVC capacities for greater integration and efficiency.
Raw Material and Geopolitical Headwinds
The West Asia conflict has introduced volatility in global supply chains and raw material prices, with energy costs increasing by approximately 15%. While the impact on Q4 FY26 was minimal, inflationary pressures are expected to be more pronounced in Q1 FY27. Epigral's diversified product portfolio is expected to provide resilience against these market fluctuations, though management noted that stabilization of supply lines will take time.
Finance Costs and Forex Impact
The company's finance cost for FY26 significantly exceeded initial guidance, reaching INR 72 crores. This increase was primarily due to a mark-to-market impact🌐 on a foreign exchange derivative loan, stemming from an unusual depreciation of the Indian Rupee (more than the historical 2-3% over the last 1.5 years). Management acknowledged the unexpected volatility and stated that the finance team is actively working on mitigation strategies.
Greenfield Project and Sustainability Initiatives
Epigral is evaluating new greenfield projects for further expansion, with an announcement expected within FY27, aiming for consistent growth beyond FY29-30. In its sustainability efforts, the company currently sources 8-9% of its power from wind-solar energy. With an additional 19.50 MW wind-solar capacity, this share is projected to increase to approximately 15% of its total power requirement.